Research Article
Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Table 2
Overall response, AFP response, and failure pattern after treatment.
| | IMRT + sorafenib (n = 36) | IMRT (n = 46) | value | n (%) | n (%) |
| Overall response | | | 0.120 | CR | 0 (0.0) | 1 (2.2) | | PR | 22 (61.1) | 20 (43.5) | | SD | 10 (27.8) | 13 (28.3) | | PD | 4 (11.1) | 12 (26.0) | | AFP response | | | 0.003 | ≥20% | 22 (61.1) | 13 (28.3) | | <20% | 14 (38.9) | 33 (71.7) | | Failure pattern | | | | In-field recurrence | 7 (19.4) | 16 (34.8) | 0.125 | Out-field recurrence | 14 (38.9) | 12 (26.1) | 0.216 | Distant metastasis | 6 (16.7) | 8 (17.4) | 0.931 |
|
|
CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.
|